Zheng Quan Zhi Xing·2025-06-05 16:17Core Viewpoint - The company, Shanghai Aopumai Biotechnology Co., Ltd., is planning to acquire 100% equity of Pengli Biological Technology (Shanghai) Co., Ltd. through a combination of issuing shares and cash payment, involving multiple investment partners [1][2]. Group 1: Transaction Details - The acquisition involves several investment entities, including PharmaLegacy Hong Kong Limited and various limited partnerships, indicating a broad consortium of investors [1]. - The company intends to raise supporting funds by issuing shares to no more than 35 specific investors as part of the transaction [1]. Group 2: Confidentiality Measures - The company has implemented strict confidentiality measures to prevent the leakage of sensitive information related to the transaction, including the establishment of a registration system for insider information [2]. - The independent financial advisor has confirmed that the company has adhered to relevant laws and regulations, ensuring effective confidentiality protocols are in place [2].